Nine companies, including SF Express, Aggregate Data, Jinyuan Hydrogen Energy, Weisheng Pharmaceutical, Shenghe Biotech, Egg, and Baide Medical, are planning to be listed in Hong Kong/US to file supplementary material requirements (feedback)
Requirements for supplementary materials for overseas issuance and listing registration (September 15, 2023 to September 21, 2023)
Baide Healthcare's plan to go public with ExcelFin (XFIN.US) in the US was previously suspended on the eve of its listing in Hong Kong
The Zhitong Finance App learned that on June 26, the Chinese medical technology company Baide Medical announced that it plans to merge with ExcelFin Acquisition Corp. (XFIN.US), a special purpose acquisition company (SPAC). After the merger is completed, the company will operate as Baird Medical Investment Holdings Limited and be listed on the NASDAQ under the stock code “BDMD.” According to the merger agreement, the equity value before the merger was 300 million US dollars, and the company's implied estimated corporate price after the merger
What does it mean for Baide Healthcare (06678) to be suspended from listing and undercover scrapping?
The Zhitong Finance App learned that Baide Healthcare (06678), which had already announced that it would be listed on the Hong Kong Stock Exchange on October 5, issued another notice on the evening of October 3 stating that the sale would be delayed, while the dark market transaction on October 3 was deemed null and void. On October 3, Baide Medical first announced the placement results, stating that the company sold 248 million shares globally, of which Hong Kong sold about 18.18% and international placements accounted for 81.82%. The final sale price has been determined at HK$1.40 per share, or 2,000 shares per lot. It is expected that the shares will be sold at 9:00 a.m. on October 5 (Wednesday) (Hong Kong time)
Dark Market Intelligence | Baide Healthcare closed down 37.14%, with each hand eroded HK$1,040
According to previously disclosed information, the number of subscribers to Baide Medical's public placement was 3,350, and the first-hand winning rate was 100%.
Bank of China-Backed Betters Medical Raises $33 Million in Hong Kong IPO
03:52 AM EDT, 10/03/2022 (MT Newswires) -- Betters Medical Investment Holdings (HKG:6678) raised HK$259.3 million ($33 million) in net proceeds from its initial public offering in Hong Kong after pric
Weekly IPO | Wanwuyun and Zero Sports Auto were successfully listed, and the “first stock in the metaverse” Flying Yundong is in the process of offering shares
Runge Interactive and Feitian Yundong are currently offering shares. It is expected that 3 IPOs will be listed and 2 IPOs will be undersold next week.
IPO purchase Guide: Pad Healthcare (6678.HK)
Purchase suggestion: the company is one of the leading developers and providers of microwave ablation (microwave ablation) medical devices for minimally invasive tumor treatment in China. The company focuses on areas of expertise with significant synergy and huge market growth potential with microwave ablation technology, including (I) benign tumors, especially thyroid and breast nodules, and (ii) malignant tumors, especially liver and lung cancer. The company has a large market share. According to Frost Sullivan data, the company treats thyroid nodules and breast nodules in China according to the sales revenue and sales volume of microwave ablation needles in 2021.
BoC-Backed Betters Medical Braves Market Volatility, Launches Up to $54 Million Hong Kong IPO
01:00 AM EDT, 09/22/2022 (MT Newswires) -- Betters Medical Investment Holdings (HKG:6678) kicked off its initial public offering in Hong Kong on Thursday, undeterred by the market volatility amid conc
Betters Medical Investment Expects to Determine IPO Price by Sept. 27
Betters Medical Investment Expects to Determine IPO Price by Sept. 27
Betters Medical Investment Expects Shares to Start Trading on Hong Kong Exchange From Oct. 5
Betters Medical Investment Expects Shares to Start Trading on Hong Kong Exchange From Oct. 5
Betters Medical Investment Marketing IPO at HK$1.40-HK$1.72/Share
Betters Medical Investment Marketing IPO at HK$1.40-HK$1.72/Share
Betters Medical Investment Plans to Sell 248.0M Shares in IPO
Betters Medical Investment Plans to Sell 248.0M Shares in IPO
Betters Medical Investment Seeks to Raise Up to HK$426.50M in Hong Kong IPO
Betters Medical Investment Seeks to Raise Up to HK$426.50M in Hong Kong IPO
The gross margin is over 80%! Baide Medical sprinted to IPO, the third largest microwave ablation medical device vendor in China
The Hong Kong Stock Exchange recently revealed that Baide Healthcare has passed the Hong Kong Stock Exchange hearing, with Bank of China International and Chinatai International as co-sponsors.
Weekly IPOs | New energy powerhouse China Innovation Airlines passes the news, Tencent Music will log on to the Hong Kong Stock Exchange next week
There was news from China Innovation Airlines this week that Dorm Health performed well on the first day of listing. Tencent Music, the largest online music and entertainment platform in China, will be listed on the main board of the Stock Exchange by introducing the listing.
Baide Medical passed the Hong Kong Stock Exchange hearing. The company is the third largest supplier of microwave ablation medical devices in China
The company is one of the leading developers and providers of microwave ablation (microwave ablation) medical devices for minimally invasive treatment of tumors in China.
Baide Healthcare once again submits a prospectus to go public in Hong Kong
On April 7, 2022, Baide Healthcare submitted a prospectus to the Hong Kong Stock Exchange for IPO listing on the Hong Kong Main Board. This is another submission following the invalidity of its prospectus submitted on September 28, 2021.
The gross margin is over 90%, comparable to medical aesthetics! Microwave ablation needle manufacturer “Baide Healthcare” plans to go to Hong Kong stocks | IPO news
Microwave ablation is a minimally invasive cancer treatment that has developed rapidly at home and abroad in recent years. It has the advantages of low trauma, high efficiency, complete local inactivation of tumors, and few complications. Baide Medical Investment Holdings Limited (“Baide Healthcare”) is a developer and provider of microwave ablation medical devices for minimally invasive cancer treatment. The company's proprietary microwave ablation medical devices are used to treat benign tumors and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast masses. The company submitted a listing application to the main board of the Hong Kong Stock Exchange on September 28 to prepare for listing in Hong Kong. Baide Healthcare was founded in 2012 by Ms. Wu Meimei
Hong Kong stock IPO | Pak Tak Medical submitted the form to HKEx, with a net profit of 27.006 million yuan in the first half of the year.
On September 30th, Capital State learned that Pak Tak Medical submitted a prospectus to the Hong Kong Stock Exchange for listing on Hong Kong's main board IPO. According to the prospectus, Baide Medical is a developer and provider of microwave ablation medical devices for minimally invasive treatment of tumors in China. The company's proprietary microwave ablation medical devices are used to treat benign and malignant tumors with increasing incidence in China, including thyroid nodules, liver cancer, lung cancer and breast masses. At present, Pak Medical's product supply and pipeline products mainly include microwave ablation therapeutic instruments and microwave ablation needles used in conjunction with therapeutic instruments. During the track record period, Baide
New stock news | Pak Tak Medical delivery form HKEx, focusing on microwave ablation of medical devices
Zhitong Financial APP learned that according to the disclosure of the HKEx on September 28th, Pak Tak Medical Investment Holdings Limited (Betters Medical Investment Holdings Limited) (hereinafter referred to as "Pak Tak Medical") submitted an application for listing on the main board to the HKEx, with Bank of China International and Zhongtai International as its co-sponsors. Baide Medical is a developer and provider of microwave ablation medical devices for minimally invasive treatment of tumors in China. The company's proprietary microwave ablation medical devices are used to treat benign and malignant tumors with a rising incidence in China, including thyroid gland.
No Data